<DOC>
	<DOCNO>NCT01308346</DOCNO>
	<brief_summary>The target enrollment goal trial enroll 36 subject . However due challenge protocol inclusion/ exclusion criterion , one subject enrol since trial initiate June 2011 . To evaluate follow participant undergo coronary artery scaffolding/stenting significant coronary artery disease : - The acute ( post-implantation ) effect implant bioresorbable vascular scaffold ( BVS ) metallic drug elute stent ( mDES ) coronary blood flow physiological responsiveness target coronary artery - The long-term ( 2 year ) effect implant BVS mDES coronary blood flow physiological responsiveness target coronary artery</brief_summary>
	<brief_title>ABSORB PHYSIOLOGY Clinical Investigation</brief_title>
	<detailed_description>- Prospective , randomize , single-blinded , multi-center clinical investigation compare target vessel non-intervened , self-control vessel within participant participant undergo BVS mDES deployment treatment single de novo native coronary artery lesion - The investigation include two arm : - Study device ( BVS ) arm : Abbott Vascular 's Everolimus-Eluting Bioresorbable Vascular Scaffold - Control device ( mDES ) arm : Abbott Vascular 's Everolimus-Eluting XIENCE V XIENCE PRIME</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Participant must male least 18 year age female postmenopausal hormone replacement therapy . 2 . Participant able verbally confirm understand risk , benefit treatment alternative he/she his/her legally authorize representative must provide write informed consent prior clinical investigation related procedure , approve appropriate Ethics Committee respective clinical site . 3 . Participant must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia positive functional study ) . 4 . Participant must acceptable candidate coronary artery bypass graft ( CABG ) surgery . 5 . Participant must agree undergo clinical investigation planrequired followup visit . 6 . Participant must agree participate clinical investigation period 2 year follow index procedure . This include clinical trial medication invasive procedure . Only questionnairebased study allow . Angiographic 1 . A single de novo native coronary artery lesion suitable treat either BVS mDES . 2 . Target lesion must locate native coronary artery mean proximal distal vessel diameter target lesion ( Dmean ) fall within range ≥ 2.25 mm ≤ 3.25 mm target lesion length measure ≤ 22 mm assess IVUS . 3 . Target lesion must locate main branch major epicardial vessel ( i.e. , LAD , LCX , RCA ) visually estimate diameter stenosis ≥ 50 % &lt; 100 % TIMI flow ≥ 1 . 4 . Participant must additional angiographically smooth ( &lt; 40 % diameter stenosis ) nontarget vessel act intraparticipant control vessel ( selfcontrol vessel ) . The selfcontrol vessel must main branch major epicardial vessel ( i.e. , LAD , LCX , RCA ) . 5 . Coronary anatomy must suitable IVUS , OCT , pressure flow wire instrumentation . General 1 . Participant know diagnosis spontaneous acute myocardial infarction ( AMI ) within 14 day precede index procedure . 2 . Participant highrisk acute coronary syndrome ( e.g. , dynamic STT wave change ECG recurrent chest pain/nitrateunresponsive prolong chest pain rest within 48 hour prior index procedure ) . 3 . Participant evidence myocardial infarct territory subtend propose target vessel selfcontrol vessel . 4 . Participant current unstable arrhythmia . 5 . Participant chronic atrial fibrillation . 6 . Participant know left ventricular ejection fraction ( LVEF ) &lt; 40 % . 7 . Participant receive heart transplant organ transplant wait list organ transplant . 8 . Participant previously CABG mitral aortic valve repair/replacement . 9 . Participant receive schedule receive chemotherapy malignancy within 30 day prior index procedure . 10 . Participant receive immunosuppressant therapy know immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , etc. ) . 11 . Participant chronic systemic condition medication likely interfere coronary physiology and/or conduit artery function ( e.g. , chronic inflammatory condition , chronic renal failure , chronic obstructive pulmonary disease ) . 12 . Participant know renal insufficiency . 13 . Participant receive schedule receive plan radiotherapy . 14 . Participant receive chronic anticoagulation therapy ( e.g. , heparin , coumadin ) onset clinical investigation . 15 . Participant know hypersensitivity contraindication aspirin , heparin/bivalirudin , antiplatelet medication specify use study ( clopidogrel , prasugrel ticlopidine , inclusive ) , everolimus , poly ( Llactide ) , poly ( DLlactide ) , cobalt , chromium , nickel , platinum , tungsten , acrylic fluoro polymer , contrast sensitivity adequately premedicated . 16 . Elective surgery plan within first 6 month index procedure require discontinue aspirin , clopidogrel , prasugrel , ticlopidine . 17 . Participant platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) within 7 day prior index procedure . 18 . Participant history bleed diathesis coagulopathy refuse blood transfusion . 19 . Participant cerebrovascular accident/stroke ( CVA ) transient ischemic neurological attack ( TIA ) within past 6 month . 20 . Participant significant gastrointestinal significant urinary bleed within past 6 month . 21 . Participant extensive peripheral vascular disease precludes safe 6 French sheath insertion . 22 . Participant history paradoxical exerciseinduced vasoconstriction consistent myocardial bridging coronary anatomy . 23 . Participant medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) judgment Investigator may cause noncompliance clinical investigation plan , confound data interpretation associate limited life expectancy . 24 . Participant currently participate another clinical investigation yet reach primary endpoint . 25 . Percutaneous intervention lesion third major epicardial vessel ( one contain target selfcontrol vessel ) perform within 30 day precede index procedure plan do within 6 month follow index procedure . 26 . Planned PCI procedure target vessel ( and/or side branch ) selfcontrol vessel ( and/or side branch ) within 2 year follow index procedure . 27 . Participant suspend drug influence vasofunction . Angiographic Exclusion Criteria 1 . Target lesion meet follow criterion : 1 . Left main location ; 2 . RCA aortoostial location ( within 10 mm expect proximal stent/scaffold edge ) ; 3 . LAD LCX ostial location ( within 10 mm expect proximal stent/scaffold edge ) ; 4 . Involves bifurcation side branch ≥ 2 mm diameter , ostial lesion &gt; 40 % stenosed visual estimation , side branch require predilatation ; 5 . Total occlusion ( TIMI flow 0 ) prior wire crossing ; 6 . Excessive tortuosity proximal within lesion ; 7 . Extreme angulation ( ≥ 90° ) proximal within lesion ; 8 . Heavy calcification lesion ; 9 . Located side branch . 2 . Participant high probability procedure predilatation , scaffold/stent implantation , postdilatation ( applicable ) require time index procedure treatment target vessel ( e.g. , atherectomy , cut balloon brachytherapy ) . 3 . The target vessel ( and/or side branch ) selfcontrol vessel ( and/or side branch ) contain visible thrombus . 4 . The target vessel selfcontrol vessel previously treat PCI procedure . 5 . A side branch target vessel side branch selfcontrol vessel receive percutaneous intervention within 30 day prior index procedure . 6 . Another clinically significant lesion locate target vessel ( and/or side branch ) selfcontrol vessel ( and/or side branch ) may require PCI treatment within 2 year follow index procedure . 7 . Participant evidence myocardial bridging coronary anatomy angiographic evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Bioabsorbable</keyword>
	<keyword>Coronary Stent</keyword>
	<keyword>Everolimus</keyword>
	<keyword>drug elute stent</keyword>
	<keyword>stent</keyword>
	<keyword>angioplasty</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>total coronary occlusion</keyword>
	<keyword>coronary artery restenosis</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>coronary artery stenosis</keyword>
</DOC>